Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study
Mahmood Mahajna, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, Ilan Matok, Haoming Zhang · 2023
Read Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study by Mahmood Mahajna, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, Ilan Matok, Haoming Zhang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10740827.txt.
Description
Mahajna and co-authors test whether a gene based drug test predicts how depressed patients fare on two common antidepressants. Both drugs are broken down by one liver enzyme, CYP2C19, whose inherited variants speed or slow the job. Their 2023 study follows 283 outpatients with test results on file and tracks side effects, adherence, and treatment changes over time.
Patients whose genes implied faster enzyme action tolerated the drugs better, with odds of intolerance falling per step of activity. A grouping analysis split patients into two camps: one with many side effects, poor adherence, and frequent switches, the other smooth on all three. Gene status strongly predicted camp membership. The authors say the test carries real predictive value for these medicines.
Catalog record
| CREATOR | Mahmood Mahajna, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, Ilan Matok, Haoming Zhang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |